Short answer: Keytruda (pembrolizumab) and other PD-1/PD-L1 inhibitors are all very expensive, and the cost per cycle is usually in a similar range. The exact amount you pay depends a lot on the dosing schedule for the indication, vial sizes, and what discounts or rebates your payer has negotiated. So, there isn’t a simple “Keytruda is cheaper/more expensive than X” answer that holds in all cases.
What influences price when you compare Keytruda to its competitors
- Dosing schedule and cycle length: Some drugs are given every 3 weeks, others every 2 weeks, 4 weeks, or every 6 weeks. A drug with a longer interval can feel cheaper per cycle even if the per-dose price is similar.
- Dose per cycle and vial usage: The number of vials needed per infusion varies by drug and patient weight, which affects waste and total drug cost per cycle.
- Indication and duration: Different cancers use different dosing regimens and typical treatment durations, so the cost per patient over a course of therapy can differ.
- Payer discounts, rebates, and negotiated prices: The actual price after rebates is often much lower than the listed price, and varies by insurer, patient assistance programs, and country.
- Country/market: Prices are higher in the US than in many other countries, and pricing structures (list price vs. net price) differ by country.
- Access programs: Manufacturer patient assistance programs, discounts, and copay supports can significantly reduce out-of-pocket costs for eligible patients.
If you want a more concrete comparison, I can tailor it if you tell me:
- Which country or region (US, Europe, etc.)
- The exact indication or regimen you’re looking at (e.g., dosing schedule like 200 mg every 3 weeks vs 400 mg every 6 weeks for Keytruda)
- Whether you want list prices or estimated out-of-pocket costs with typical insurance
I can then give a clearer, side-by-side estimate for Keytruda and its main competitors (Opdivo, Tecentriq, Imfinzi, Libtayo) based on that regimen.